Contact    |    Site Map    |    Careers
The Acetylon Story: Working to make a meaning difference
Multiple Myeloma Clinical Trials
The Promise of Epigenetics to enhance therapeutics outcomes
Acetylon_story Clinical_trials Future_directions

Building on the Promise of Epigenetics to Enhance Therapeutic Outcomes

Acetylon Pharmaceuticals, Inc. is building on the promise of epigenetics by applying its unique capabilities to discover and develop next-generation, selective small molecule drugs for the treatment of patients with critical unmet medical needs. The Company is focused on development of safe, selective inhibitors of histone deacetylases (HDACs) active in the treatment of cancer, neurodegeneration, autoimmune disease and other life-threatening diseases. Acetylon’s lead drug candidate, ricolinostat (ACY-1215), is currently in clinical trials for the treatment of multiple myeloma and lymphoma. The Company is located in Boston and is based on technology initially developed at the Dana-Farber Cancer Institute and at Harvard University.